Polyclonal Antibody to Single Ig IL1 Related Receptor (SIGIRR)
Code | Size | Price |
---|
PAM229Ra01-20ul | 20ul | £97.00 |
Quantity:
PAM229Ra01-100ul | 100ul | £187.00 |
Quantity:
PAM229Ra01-200ul | 200ul | £254.00 |
Quantity:
PAM229Ra01-1ml | 1ml | £590.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
TIR8; Single Ig IL-1R-related molecule; Toll/interleukin-1 receptor 8; Single immunoglobulin domain-containing IL1R-related protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Single Ig IL1 Related Receptor
Reactivity:
Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:500-2000
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:50-200
Immunocytochemistry: 5-20ug/mL;1:50-200
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Single Ig IL1 Related Receptor (SIGIRR) | RPM229Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||